- β-blocker use at the time of cytoreductive surgery is associated with worse OS in patients with advanced ovarian cancer.
- 90% of patients receiving β-blockers received a cardioselective β-blocker.
Why this matters
- Most patients received cardioselective β-blockers in the current study, and any survival benefit gained in previous reports might be driven by the actions of noncardioselective β-blockers.
- 534 women with stage IIIC and IV epithelial ovarian cancer underwent primary or interval cytoreduction.
- Funding: None disclosed.
- 84.8% of women had serous carcinoma.
- 105 women reported receiving a β-blocker, of whom 90% received a cardioselective β-blocker.
- The most common β-blockers were metoprolol (47%) and atenolol (38%).
- Median OS was significantly lower in β-blocker users vs nonusers (29 vs 35 months; P=.007).
- Median PFS was similar in the 2 groups (P=.953).
- β-blocker use was associated with worse OS (adjusted HR, 1.57; P=.006) after adjusting for age, race, age-adjusted Charlson comorbidity index, stage, triage to neoadjuvant chemotherapy, histology, residual disease status, statin use, metformin use, and aspirin use.
- Risk factors for mortality (HR) included:
- Nonwhite patients (black/Asian/Hispanic/others) vs white patients: 1.85 (P<.001>
- Triage to neoadjuvant chemotherapy/interval debulking surgery: 1.74 (P<.001>
- Suboptimal debulking procedure: 1.76 (P=.006).
- Retrospective design.